coronaviru
diseas
becom
global
pandem
current
mani
drug
show
potenti
therapi
howev
genet
factor
lead
differ
drug
effici
toxic
among
popul
still
undisclos
therapi
select
potenti
drug
therapi
dct
clinic
guidelin
clinic
trial
databas
pharmacogen
relat
therapeut
drug
includ
variat
inform
exom
collect
racial
differ
analys
express
level
pharmacogen
singl
cell
resolut
evalu
singlecel
rna
sequenc
scrnaseq
data
healthi
adult
result
pharmacogen
includ
alb
involv
process
multi
dct
potenti
drugdrug
interact
ddi
dct
predict
report
racial
discrep
common
nonsynonym
mutat
found
pharmacogen
includ
vdr
itpa
relat
dct
includ
ribavirin
interferon
chloroquin
lopinavir
moreov
target
found
part
lung
cell
make
drug
like
chloroquin
prevent
viru
bind
specif
target
drug
camostat
mesyl
end
last
year
wuhan
capit
citi
hubei
provinc
china
report
new
unknown
viral
pneumonia
subsequ
next
gener
sequenc
identifi
caus
novel
coronaviru
name
novel
coronaviru
clinic
characterist
report
china
reveal
patient
mild
moder
howev
sever
case
progress
rapidli
acut
respiratori
distress
syndrom
ard
shock
multipl
organ
failur
even
death
nation
health
commiss
china
releas
least
seven
version
guidelin
diagnosi
treatment
pneumon
caus
oxygen
therapi
mechan
ventil
drug
therapi
recommend
major
treatment
sever
drug
may
util
simultan
condit
noteworthi
individu
differ
drug
treatment
mention
special
guidelin
promot
import
person
therapi
patient
lifethreaten
sever
hemolysi
take
chloroquin
one
common
human
enzym
defect
genet
variant
affect
activ
show
remark
individu
ethnic
differ
thu
wide
inform
chloroquin
need
precis
medicin
addit
chloroquin
number
drug
also
use
therapi
rapid
spread
diseas
worldwid
drug
use
patient
differ
ethnic
background
howev
genet
variant
potenti
affect
effect
safeti
still
avail
distribut
differ
popul
world
also
indic
may
constitut
obstacl
success
treatment
control
diseas
pharmacogenet
pgx
investig
affect
genet
variant
drug
effect
safeti
current
studi
provid
pgx
landscap
drug
potenti
use
treatment
candid
choic
differ
drug
base
pharmacogenet
analys
provid
drug
clinic
trial
inform
treatment
col
lect
guidelin
diagnosi
treatment
pneumon
caus
c
version
http
clinic
trail
http
clinicaltrialsgov
chine
se
clinic
trail
registri
http
wwwchictrorgcn
pharmacogen
relat
elin
genet
variat
data
gene
retriev
gnom
ad
databas
http
gnomadbroadinstituteorg
version
final
singlecel
l
rna
sequenc
scrna
seq
data
two
organ
liver
lung
healthi
adult
download
geo
da
tabas
http
wwwncbinlmnihgovgd
raw
count
matrix
uniqu
molecular
identifi
count
per
gene
per
cell
process
seurat
firstli
lowqual
data
filter
follow
cell
express
less
gene
gene
express
less
two
percent
cell
secondli
calcul
log
countpermillion
express
follow
normal
standard
thirdli
cell
cluster
detail
highli
variabl
gene
identifi
cell
cluster
embed
graph
structur
princip
compon
analysi
space
paramet
resolut
set
identifi
major
cell
type
cluster
cell
project
onto
twodimension
space
visual
final
differenti
express
gene
cluster
identifi
use
annot
merg
cell
cluster
accord
curat
known
cell
marker
http
biocchrbmueducncellmarkerindexjsp
genet
variat
annot
allel
frequenc
locat
function
differ
popul
use
annovar
version
tabl
current
studi
popul
divid
eight
categori
african
latino
east
asian
south
asian
finnish
nonfinnish
european
ashkenazi
jewish
base
locat
function
mutat
divid
categori
frameshift
nonframeshift
synonym
singl
nucleotid
polymorph
snp
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
nonsynonym
snp
stopgain
untransl
region
intron
other
includ
splice
upstream
gene
downstream
gene
stoploss
ncrnaexon
mutat
function
nonsynonym
mutat
predict
provean
http
proveanjcviorg
druggen
network
construct
cytoscap
softwar
current
studi
total
drug
collect
studi
includ
agent
use
clinic
undergo
clinic
trial
confirm
vitro
experi
simpli
therapeut
potenti
could
classifi
nine
categori
accord
function
viral
toxic
sensit
inhibit
viru
invas
improv
lung
function
maintain
tissu
organ
function
balanc
antihypox
antisept
shock
antisecondari
infect
other
figur
among
antivir
drug
mostli
import
account
drug
includ
viru
invas
inhibitor
viral
toxic
sensit
march
total
clinic
trial
conduct
studi
safeti
efficaci
antivir
drug
clinic
trial
ongo
complet
six
clinic
trial
involv
remdesivir
earliest
close
one
involv
particip
complet
april
mani
clinic
trial
relat
chloroquin
two
clinic
trial
mild
common
patient
sever
patient
complet
april
clinic
trial
includ
total
particip
hydroxychloroquin
two
nine
clinic
trial
end
februari
result
yet
avail
addit
clinic
trial
lopinavir
ritonavir
complet
earli
march
inform
categori
drug
found
figur
genet
variat
one
power
biomark
guid
person
therapi
thu
import
systemat
identifi
pharmacogen
could
affect
respons
toxic
drug
druggen
network
demonstr
connect
drug
pharmacogen
construct
figur
exclud
drug
without
pharmacogen
data
total
drug
gene
connect
base
node
network
could
easili
find
gene
share
multipl
drug
could
mediat
drugdrug
interact
ddi
figur
addit
genet
variat
could
potenti
affect
respons
toxic
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
anoth
inform
obtain
network
action
pgx
biomark
three
drug
base
cpic
dpwg
guidelin
chloroquin
hemolysi
toxic
vitamin
receptor
vdr
ribavirin
efficaci
inosin
triphosphatas
itpa
anemia
risk
angiotensin
convert
enzym
ace
captopril
respons
recommend
gene
preemptiv
test
drug
treatment
next
investig
allel
frequenc
locat
function
genet
mutat
pharmacogen
differ
popul
total
number
variat
gene
found
subject
gnomad
databas
although
mutat
distribut
gene
region
common
mutat
type
intron
nonsynonym
synonym
mutat
figur
noteworthi
mutat
nonsynonym
major
type
function
pgx
variant
could
explan
individu
ethnic
differ
drug
treatment
learn
distribut
mutat
pharmacogen
detail
fraction
differ
mutat
type
provid
gene
summar
base
gene
function
figur
frequenc
variat
indic
figur
show
similar
distribut
howev
remark
differ
total
number
mutat
explor
allel
frequenc
mutat
indic
figur
mutat
rare
genet
variant
minor
allel
frequenc
maf
lower
result
emphas
import
pharmacogenom
scale
test
treatment
analyz
mutat
differ
maf
stratifi
popul
except
african
popul
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
signific
differ
maf
distribut
remain
seven
race
figur
african
individu
higher
genet
variabl
pharmacogen
sinc
show
percentag
common
mutat
maf
result
indic
higher
requir
pgx
test
taken
togeth
result
indic
pharmacogen
highli
genet
variabl
especi
african
popul
thu
person
drug
treatment
pgx
test
need
differ
patient
addit
mutat
distribut
gene
region
rare
variat
figur
therefor
sequenc
technolog
recommend
preemptiv
test
provid
clinic
guid
treatment
analyz
action
key
pgx
biomark
detail
four
pair
action
pharmacogen
drug
vdr
ribavirin
itpa
chloroquin
ace
captopril
ribavirin
classic
antiviru
drug
involv
guidelin
therapi
well
vdr
polymorph
associ
efficaci
figur
common
nonsynonym
polymorph
could
hamper
vdr
activ
carrier
show
lower
efficaci
frequenc
mutat
popul
figur
mean
half
patient
resist
drug
interferon
usual
util
combin
antiviru
drug
ribavirin
treatment
itpa
polymorph
report
associ
anemia
risk
treatment
figur
function
mutat
reduc
activ
enzym
encod
itpa
carrier
show
lower
anemia
risk
anoth
common
nonsynonym
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
polymorph
also
found
itpa
figur
effect
reveal
identifi
asian
east
asian
south
asian
figur
therefor
asian
may
higher
anemia
risk
treatment
chloroquin
util
therapi
guidelin
refer
polymorph
report
associ
hemolysi
risk
figur
two
import
variant
could
decreas
function
carrier
show
higher
hemolysi
risk
chloroquin
treatment
addit
two
mutat
identifi
three
common
nonsynonym
polymorph
popul
among
mutat
also
report
decreas
activ
indic
mutat
could
increas
hemolysi
risk
well
common
african
popul
figur
suggest
chloroquin
recommend
african
patient
lopinavir
ritonavir
use
togeth
reduc
metabol
liver
inhibit
activ
import
enzym
could
metabol
half
dct
polymorph
cyp
link
increas
activ
thu
facilit
metabol
drug
like
lopinavir
carrier
may
need
increas
dosag
drug
compar
wild
type
patient
figur
anoth
common
nonsynonym
polymorph
still
report
phenotyp
figur
east
asian
figur
indic
east
asian
may
metabol
lopinavir
ritonavir
rapidli
mention
pump
mani
drug
across
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
cellular
membran
thu
allevi
efficaci
drug
list
drug
like
lopinavir
transport
cell
efficaci
reduc
figur
found
common
nonsynonym
polymorph
figur
among
report
deleteri
mutat
increas
drug
concentr
decreas
efflux
carrier
found
popul
high
frequenc
african
carrier
almost
east
asian
carrier
european
figur
patient
may
respons
drug
transport
addit
ace
inhibitor
acei
use
improv
lung
function
treatment
wide
report
ace
polymorph
could
affect
acei
therapeut
respons
figur
import
variant
id
polymorph
low
frequenc
indel
mutat
caus
low
enzym
express
allel
carrier
show
better
respons
acei
treatment
addit
mutat
identifi
common
nonsynonym
polymorph
popul
figur
although
relat
report
variat
predict
lossoffunct
mutat
provean
thu
specul
patient
harbor
singl
nucleotid
polymorph
snp
poor
respond
drug
base
maf
differ
popul
identifi
east
asian
popul
figur
thu
conclud
east
asian
patient
could
resist
drug
summari
african
patient
could
hazard
chloroquin
asian
patient
higher
risk
anemia
treatment
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
recent
scrna
seq
technolog
rapidli
develop
capabl
specif
profil
cell
popul
singlecel
resolut
thu
transform
mani
field
genom
research
tri
explor
util
scrna
seq
person
treatment
collect
healthi
adult
scrna
seq
data
lung
liver
tissu
lung
major
attack
organ
thu
analyz
express
viru
drug
target
gene
differ
lung
cell
figur
base
current
find
transmembran
serin
proteas
two
major
target
viru
drug
indic
figur
almost
express
kind
cell
enrol
drug
camostat
mesyl
act
trypsin
like
proteas
inhibitor
could
potenti
use
antiviru
inhibit
activ
due
ubiquit
express
target
camostat
mesyl
could
also
caus
potenti
toxic
exert
therapeut
effect
hand
mainli
express
type
pneumocyt
type
ii
pneumocyt
club
mast
cell
chloroquin
phosphat
chang
structur
inhibit
bind
coronaviru
protein
base
data
chloroquin
effect
target
drug
less
side
effect
figur
scrna
seq
data
lung
tissu
suggest
target
drug
chloroquin
superior
treatment
target
drug
camostat
mesyl
drug
metabol
liver
next
analyz
express
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
drug
metabol
enzym
differ
liver
cell
figur
major
enzym
respons
drug
metabol
express
investig
figur
addit
hepatocyt
unexpect
found
enzym
also
found
highli
express
immun
cell
base
express
distribut
categor
enzym
two
group
figur
therefor
leflunomid
may
recommend
immunosuppress
drug
avail
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
sinc
mani
candid
drug
therapi
import
make
better
choic
patient
found
tabl
larg
part
drug
metabol
liver
activ
famili
may
impact
mani
drug
metabol
rate
due
activ
differ
exist
among
popul
genotyp
import
allel
famili
detect
diagnosi
treatment
strategi
drug
suggest
patient
meanwhil
ddi
also
consid
mani
drug
may
util
togeth
treatment
mention
instanc
drug
like
lopinavir
ritonavir
inhibit
activ
thu
drug
dosag
adjust
combin
drug
metabol
drug
metabol
famili
therapi
list
tabl
addit
chloroquin
util
drug
like
losartan
increas
concentr
chloroquin
may
replac
valsartan
valid
ddi
drug
treatment
given
tabl
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
final
base
current
research
infect
cell
indic
express
cell
found
larg
part
cell
drug
like
camostat
mesyl
recommend
compar
specif
inhibitor
due
side
effect
caus
uninfect
cell
studi
firstli
focus
pharmacogenet
provid
clinic
suggest
precis
medicin
treatment
systemat
dct
show
associ
least
one
gene
druggen
network
highlight
multi
drug
relat
gene
treatment
meanwhil
interraci
varianc
drug
efficaci
found
relat
nonsynonym
mutat
among
differ
race
indic
racial
special
strategi
therapi
consid
outbreak
worldwid
sinc
nonsynonym
mutat
gene
express
level
affect
dct
efficaci
toxic
mention
optim
therapi
strategi
need
benefit
affect
patient
world
studi
give
three
suggest
dct
follow
firstli
drug
cpic
guidelin
includ
ribavirin
interferon
chloroquin
captopril
util
genet
detect
guid
situat
adequ
gene
detect
kit
prepar
africa
therapi
relat
genet
variat
frequenc
higher
afr
countri
secondli
drug
chloroquin
whose
efficaci
toxic
determin
nonsynonym
mutat
may
prefer
special
popul
lower
frequenc
risk
allel
finnish
nonfinnish
european
otherwis
altern
drug
chloroquin
use
high
risk
popul
thirdli
drug
inhibit
activ
ddi
prevent
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
treatment
tabl
inhibitor
util
dosag
drug
adjudg
care
avoid
overdosag
although
precis
medicin
consid
treatment
still
mani
challeng
face
first
challeng
pharmacogen
mani
drug
still
clear
due
mani
newli
develop
drug
still
clinic
trial
pharmacogen
hardli
fulli
identifi
current
potenti
solut
predict
candid
pharmacogen
accord
chemic
structur
new
drug
artifici
intellig
machin
learn
algorithm
relat
molecular
biolog
studi
conduct
valid
candid
pharmacogen
rapidli
period
pharmacogen
identif
short
second
challeng
seriou
nonsynonym
mutat
hardli
identifi
current
pharmacogenet
studi
due
frequenc
mani
nonsynonym
mutat
lower
nonsynonym
mutat
present
common
variant
patient
carri
seriou
nonsynonym
mutat
relat
studi
hardli
conduct
identifi
mutat
limit
sampl
size
howev
indic
figur
nonsynonym
mutat
rare
variat
therefor
reliabl
way
predict
potenti
pharmacogenet
variat
also
import
improv
efficaci
avoid
seriou
toxic
third
challeng
suitabl
strategi
precis
medicin
treatment
still
lack
welldesign
gene
detect
panel
import
fulli
character
patient
genotyp
relat
drug
effect
best
treatment
regimen
util
patient
efficaci
safeti
guarante
studi
feasibl
suggest
given
still
much
improv
develop
pharmacogenet
studi
futur
last
least
express
level
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
pharmacogen
patient
hardli
detect
singl
cell
resolut
treatment
although
express
level
gene
associ
drug
efficaci
toxic
potenti
solut
build
systemat
pharmacogen
express
map
singl
cell
level
among
differ
popul
differ
age
stage
map
would
help
person
medicin
futur
work
support
nation
natur
scienc
foundat
china
author
declar
conflict
interest
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
color
column
color
drug
indic
categori
drug
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
